Belatacept
Pre-clinicalCompleted 2 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease
Trial Timeline
Mar 1, 2012 → Mar 1, 2018
NCT ID
NCT01496417About Belatacept
Belatacept is a pre-clinical stage product being developed by Bristol Myers Squibb for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01496417. Target conditions include End-Stage Renal Disease.
What happened to similar drugs?
8 of 9 similar drugs in End-Stage Renal Disease were approved
Approved (8) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00719225 | Pre-clinical | Completed |
| NCT02939365 | Approved | Withdrawn |
| NCT03375138 | Phase 1 | Completed |
| NCT02327403 | Phase 2 | Completed |
| NCT01953120 | Approved | Completed |
| NCT01791491 | Phase 2 | Completed |
| NCT01496417 | Pre-clinical | Completed |
| NCT01033500 | Pre-clinical | Withdrawn |
| NCT00578448 | Phase 2 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease